HAE vs. BSX: Which Stock Is the Better Value Option?

Right now, both Haemonetics and Boston Scientific are sporting a Zacks Rank of # 2 (Buy). The Zacks Rank favors stocks that have recently seen positive revisions to their earnings estimates, so investors should rest assured that both of these companies have improving earnings outlooks. But this is just one factor that value investors are interested in. Another notable valuation metric for HAE is its P/B ratio of 4.77. The P/B ratio pits a stock's market value against its book value, which is defined as tota ...